2
Clinical Trials associated with Autologous Urine-derived Stem Cells(EHL Bio) / Not yet recruitingNot ApplicableIIT A clinical study for safety and efficacy evaluation of autologous urine-derived stem cells in patients with diabetic nephropathy.
Start Date03 Feb 2025 |
Sponsor / Collaborator- |
A Single Arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Autologous Urine-derived Stem Cells, 『KDSTEM Inj.』, in Patients With Chronic Kidney Disease
A Single arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Autologous Urine-derived Stem Cells, 『KDSTEM Inj.』, in Patients with Chronic Kidney Disease.
The aim of this study is to evaluate the safety and preliminary efficacy of KDSTEM Inj. in the treatment in Patients with Chronic Kidney Disease.
100 Clinical Results associated with Autologous Urine-derived Stem Cells(EHL Bio)
100 Translational Medicine associated with Autologous Urine-derived Stem Cells(EHL Bio)
100 Patents (Medical) associated with Autologous Urine-derived Stem Cells(EHL Bio)
100 Deals associated with Autologous Urine-derived Stem Cells(EHL Bio)